Physician profile
Marki Meyer
NPI 1710636394
$9,027.18
in general payments reported to CMS, 2019-2025
37 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,341 · 2023: $3,234 · 2024: $3,097 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,621 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,620.99 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,399.79 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $1,027.08 | 2022-2025 | Afrezza |
| Lilly USA, LLC | $712.41 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.58 | 2022-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $500.68 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $478.27 | 2022-2025 | |
| Amgen INC. | $436.43 | 2022-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $390.57 | 2023-2024 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $317.99 | 2023-2024 | Farxiga, Breztri |
| Radius Health, INC. | $304.53 | 2022-2024 | Tymlos |
| Nevro Corp. | $273.01 | 2022-2024 | Senza |
| Xeris Pharmaceuticals, INC. | $270.45 | 2022-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Insulet Corporation | $266.29 | 2023-2025 | Omnipod |
| Dexcom, INC. | $249.97 | 2022-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $249.79 | 2022-2025 | Isturisa, Signifor Lar |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $214.71 | 2023-2025 | |
| Medtronic, INC. | $205.69 | 2023 | Minimed 780g, Intellis Adaptivestim |
| Tandem Diabetes Care, INC. | $185.85 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $180.27 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $126.15 | 2022-2025 | |
| Astellas Pharma US INC | $97.68 | 2024-2025 | Veozah |
| Almatica Pharma LLC | $77.05 | 2024-2025 | Teriparatide, Loreev Xr |
| Amphastar Pharmaceuticals, INC. | $68.46 | 2024-2025 | |
| Amarin Pharma, INC. | $60.04 | 2022-2023 | |
| Cequr Corporation | $56.85 | 2023 | Cequr Simplicity |
| Tolmar, INC. | $43.68 | 2023-2024 | |
| Acerus Pharmaceuticals Corporation | $43.55 | 2022 | |
| Azurity Pharmaceuticals, INC. | $39.02 | 2025 | Azmiro |
| Neurocrine Biosciences, INC. | $35.30 | 2025 | |
| Ascendis Pharma Endocrinology INC | $29.89 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $28.96 | 2024 | |
| Kyowa Kirin, INC. | $26.62 | 2023 | |
| Ibsa Pharma INC. | $23.03 | 2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $19.85 | 2023 | Onpattro |
| Alexion Pharmaceuticals, INC. | $18.36 | 2022 | |
| Alvogen INC | $17.17 | 2023 | Teriparatide |
| Eusa Pharma (US) LLC | $17.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marki Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.